

# COV1APHP - Collection of blood samples from individuals having developed SARS CoV-2 infection

Head :Launay Odile

Last update : 06/20/2025 | Version : 2 | ID : 73506

## General

### Identification

Detailed name Collection of blood samples from individuals having developed SARS CoV-2 infection

Sign or acronym COV1APHP

CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation ID-RCB: 2020-A00915-34

### General Aspects

Medical area Infectious diseases

Study in connection with Covid-19 Yes

Pathology (details) Recovered SARS-CoV-2 infection

### Scientific investigator(s) (Contact)

Name of the director Launay

Surname Odile

Address CIC 1417 Cochin-Pasteur  
Hôpital Cochin, Bâtiment Lavoisier  
27 Rue du Faubourg Saint-Jacques  
75014 PARIS

### Collaborations

Participation in projects, networks and consortia No

### Funding

### Governance of the database

Sponsor(s) or organisation(s) responsible	BIOMERIEUX
Organisation status	
Additional contact	
Name of the contact	PIGA
Surname	Nadia
Address	BioMérieux SA Immunoassays Research & Development Chemin de l'Orme 69280 MARCY L'ETOILE
Email	nadia.piga@biomerieux.com
Main features	
Type of database	
Type of database	Study databases
Database recruitment is carried out by an intermediary	A selection of health institutions and services
Database recruitment is is made on the basis of:	Another treatment or procedure
Database recruitment is carried out as part of an interventional study	Yes
Details	Performed at individual level
Additional information regarding sample selection.	Individuals having developed SARS-CoV-2 infection
Database objective	
Main objective	This study aims to develop prototype tests for the in vitro diagnostic serology of SARS-CoV-2
Inclusion criteria	Healthcare personnel or patient, having recovered from COVID-19 Individuals having developed typical symptoms of SARS-CoV-2, with a result confirmed by a PCR laboratory test on a nasopharyngeal swab, and with a blood sample taken at least 10 days after onset of symptoms Adults Individuals having been duly informed and signed

the informed consent form  
Affiliated with a French social security system

## Population type

Age  
Adolescence (13 to 18 years)  
Adulthood (19 to 24 years)  
Adulthood (25 to 44 years)  
Adulthood (45 to 64 years)  
Elderly (65 to 79 years)  
Great age (80 years and more)

Population covered      General population

## Pathology

Gender      Male  
Woman

Geography area      Regional

French regions covered by the database      Île-de-France

Detail of the geography area      APHP institutions

## Data collection

### Dates

Date of first collection (YYYY or MM/YYYY)      2020

Date of last collection (YYYY or MM/YYYY)      2020

### Size of the database

Size of the database (number of individuals)      < 500 individuals

Details of the number of individuals      100

## Data

Database activity      Data collection completed

Type of data collected      Clinical data  
Administrative data

Details of collected clinical data      Date of onset of COVID-19 symptoms, clinical

signs, name of confirmation PCR test, date of PCR test

Administrative data (detail)

Age, gender

## Procedures

Data collection method

Data collection form (1 form per participant) completed by the CIC (clinical investigation center), scanned, then transferred to BioMérieux via a secure file-sharing platform (Coltshare)

Participant monitoring

Yes

Monitoring procedures

Monitoring by contact with the participant (mail, e-mail, telephone etc.)

Details on monitoring of participants

Contact 3 days (+/- 1 day) after the blood sample, to check that the venous puncture site is healthy

Links to administrative sources

No

## Promotion and access

Promotion

Access